<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-11-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09379</drugbank-id>
  <name>Sutilain</name>
  <description>Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000 casein units of proteolytic activity.[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]</description>
  <cas-number>12211-28-8</cas-number>
  <unii>2PU6O23V1G</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32601</ref-id>
        <pubmed-id>821152</pubmed-id>
        <citation>Coopwood TB: Evaluation of a topical enzymatic debridement agent--sutilains ointment: a preliminary report. South Med J. 1976 Jul;69(7):834-6.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T169</ref-id>
        <isbn>978-81-96396-15-2</isbn>
        <citation>Kokate C., Purohit A. and Gokhale S. (2008). Pharmacognosy (42nd ed.). Pragati Book House.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L2368</ref-id>
        <title>FDA approval </title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=012828</url>
      </link>
      <link>
        <ref-id>L2383</ref-id>
        <title>US Army Annual progress report</title>
        <url>http://www.dtic.mil/dtic/tr/fulltext/u2/a021858.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases.[T169]</indication>
  <pharmacodynamics>Reports indicated that sutilain exhibited a rapid and effective debridement when used for the treatment of burns, decubiti and traumatic wounds. In the case of peripheral vascular ulcerations, it did not respond in a predictable manner.[A32601] When used, sutilain caused a rapid dissolution of the surface of the treated skin zone. However, a graftable wound bed as achieved no more rapidly than if saline soaks had been used since the enzyme appears to be ineffective in removing deep dermal elements and necrotic fat.[L2383]</pharmacodynamics>
  <mechanism-of-action>Sutilain is a proteolytic enzyme that dissolves necrotic tissue and hyaluronidase.[T170]</mechanism-of-action>
  <toxicity>The toxicity has not been determined.</toxicity>
  <metabolism>This pharmacokinetic parameter is not relevant.</metabolism>
  <absorption>Sutilain is not absorbed.</absorption>
  <half-life>This pharmacokinetic parameter is not relevant.</half-life>
  <protein-binding>This pharmacokinetic parameter is not relevant.</protein-binding>
  <route-of-elimination>This pharmacokinetic parameter is not relevant.</route-of-elimination>
  <volume-of-distribution>This pharmacokinetic parameter is not relevant.</volume-of-distribution>
  <clearance>This pharmacokinetic parameter is not relevant.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="">Sutilaina</synonym>
    <synonym language="french" coder="">Sutilaines</synonym>
    <synonym language="english" coder="">Sutilains</synonym>
  </synonyms>
  <products>
    <product>
      <name>Travase Ointment 82000 Casein Units/gm</name>
      <labeller>Boots Pharmaceuticals Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02034476</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Travase Ointment 82000 Casein Units/gm</name>
      <ingredients>Sutilain</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>3799</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910450</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>